Post

New research · Obstetrics & Gynecology
American journal of obstetrics and gynecology · 1d
Cohort studyAmerican journal of obstetrics and gynecology · 2026

Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer.

Ting-Fang Lu, Yu-Hsiang Shih, Yen-Fu Chen … Chien-Hsing Lu
Read paper
Obstetrics & GynecologyCohort study

Hormone therapy is associated with improved overall survival in young cervical cancer patients.

Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer.

Ting-Fang Lu et al. · American journal of obstetrics and gynecology · 2026
Background

Concurrent chemoradiotherapy for locally advanced cervical cancer frequently induces premature menopause in young patients, resulting in long-term metabolic, skeletal, and cardiovascular morbidity.

Purpose

To evaluate the association of hormone therapy with long-term metabolic, skeletal, cardiovascular, oncologic, and survival outcomes in young patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.

Methods

Who died or developed primary outcomes before the 1-year landmark were excluded.

n = 4,656 patients
Results
hormone therapy was associated with a better chance of living longer
n = 4,656 patients
More results

Among patients initially classified as non-HT users, 112 of 2,328 (4.8%) subsequently had recorded hormone therapy exposure after the 1-year index event.

Cumulative hormone therapy duration and discontinuation during follow-up were not reliably quantifiable in the aggregate platform.

More results

There were no significant differences in incidences of thromboembolism, breast cancer, or colorectal cancer.

“
Conclusion · 1 of 2

In this large multinational cohort of young patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy, initiating hormone therapy within the first year was associated with reduced metabolic, skeletal, and cerebrovascular morbidity and improved overall survival, without an increased risk of oncologic outcomes during long-term follow-up.

Conclusion · 2 of 2

These findings support the safety and potential systemic health benefits of hormone therapy in this undertreated population.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Randomized Trial
-2.3 percentage points
the chance of staying cancer-free for 3 years was higher with biopsy only
Randomized Trial
HR 0·42
for p53-abnormal tumors, combined treatment nearly halved the risk of cancer returning
Cohort Study
HR 0.85
The hazard of death was similar with adjuvant chemoradiotherapy versus radiotherapy alone.
Cohort Study
95.3%
adding abdominal fat thickness improved the correct identification of gestational diabetes
Cohort Study
38.1%
patients with low-grade precancerous cervical lesions missing family doctor follow-up
Cohort Study
26.4%
women with diabetes during pregnancy developed high blood pressure 5 months after birth
Cohort Study
33.3%
Among pregnant women with anemia, a higher percentage had babies born early
Randomized Trial
3.8% vs 27.5%
fewer patients experienced delayed bowel function after surgery with milk of magnesia